Skip to content

Study · Animal study (in vivo) · mouse · 2002

9 results

GH-releasing peptide-2 increases fat mass in mice lacking NPY: indication for a crucial mediating role of hypothalamic agouti-related protein.

Tschöp M, Statnick MA, Suter TM, Heiman ML

Endocrinology1 Feb 2002Cited by 106 (Europe PMC)

PMID11796511 (opens in a new tab)DOI10.1210/endo.143.2.8633 (opens in a new tab)PepBankPUB-11796511
Publisher pagePubMedAsk about this study
Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

8 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In NPY-deficient mice, the melanocortin-receptor agonist MT-II prevented the weight gain that GHRP-2 caused.

    In plain wordsIn mice lacking NPY, MT-II blocked the weight gain caused by GHRP-2.

    Peptide
    Melanotan II
    Outcome
    DecreaseGHRP-2-induced weight gain
    Study

    mousen: not reported in source

    Npy(-/-) mice
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Competitive blockade of AGRP action by melanocortin-receptor agonist MT-II prevented GHRP-induced weight gain in Npy(-/-) mice.
    1 context sentence
    Summary · context
    Because such adiposity was thought to be mediated by hypothalamic NPY neurons, we investigated by which mechanism a synthetic ghrelin receptor agonist, GHRP-2, would generate a positive energy balance in NPY-deficient [Npy(-/-) mice] and wild-type controls.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In Npy-/- and wild-type mice, daily subcutaneous GHRP‑2 caused a dose-dependent increase in body weight.

    In plain wordsIn mice, daily GHRP‑2 injections raised body weight in a dose-dependent way.

    Peptide
    GHRP-2
    Outcome
    IncreaseBody weight
    Study

    mousen: not reported in source

    Npy-/- and wild-type mice
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · subcutaneousAs given in this study (mouse).

    Source sentences

    Summary
    A dose-dependent increase in body weight and food intake was observed during daily sc injections with GHRP-2.
    1 context sentence
    Summary · context
    Because such adiposity was thought to be mediated by hypothalamic NPY neurons, we investigated by which mechanism a synthetic ghrelin receptor agonist, GHRP-2, would generate a positive energy balance in NPY-deficient [Npy(-/-) mice] and wild-type controls.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In Npy-/- and wild-type mice, daily subcutaneous GHRP‑2 caused a dose-dependent increase in food intake.

    In plain wordsIn mice, daily GHRP‑2 injections raised food intake in a dose-dependent way.

    Peptide
    GHRP-2
    Outcome
    IncreaseFood intake
    Study

    mousen: not reported in source

    Npy-/- and wild-type mice
    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    Dose not stated · subcutaneousAs given in this study (mouse).

    Source sentences

    Summary
    A dose-dependent increase in body weight and food intake was observed during daily sc injections with GHRP-2.
    1 context sentence
    Summary · context
    Because such adiposity was thought to be mediated by hypothalamic NPY neurons, we investigated by which mechanism a synthetic ghrelin receptor agonist, GHRP-2, would generate a positive energy balance in NPY-deficient [Npy(-/-) mice] and wild-type controls.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In Npy-/- and wild-type mice, GHRP‑2 treatment increased fat mass.

    In plain wordsIn mice, GHRP‑2 treatment increased fat mass.

    Peptide
    GHRP-2
    Outcome
    IncreaseFat mass
    Study

    mousen: not reported in source

    Npy-/- and wild-type mice
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · subcutaneousAs given in this study (mouse).

    Source sentences

    Summary
    Pre- and posttreatment analysis of body composition indicated increased fat mass and bone mass but not lean mass.
    1 context sentence
    Summary · context
    Because such adiposity was thought to be mediated by hypothalamic NPY neurons, we investigated by which mechanism a synthetic ghrelin receptor agonist, GHRP-2, would generate a positive energy balance in NPY-deficient [Npy(-/-) mice] and wild-type controls.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In Npy-/- and wild-type mice, GHRP‑2 treatment increased bone mass.

    In plain wordsIn mice, GHRP‑2 treatment increased bone mass.

    Peptide
    GHRP-2
    Outcome
    IncreaseBone mass
    Study

    mousen: not reported in source

    Npy-/- and wild-type mice
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · subcutaneousAs given in this study (mouse).

    Source sentences

    Summary
    Pre- and posttreatment analysis of body composition indicated increased fat mass and bone mass but not lean mass.
    1 context sentence
    Summary · context
    Because such adiposity was thought to be mediated by hypothalamic NPY neurons, we investigated by which mechanism a synthetic ghrelin receptor agonist, GHRP-2, would generate a positive energy balance in NPY-deficient [Npy(-/-) mice] and wild-type controls.
  6. 06AnimalAnimal study (in vivo)Efficacy outcome

    In Npy-/- and wild-type mice, GHRP‑2 treatment did not increase lean mass.

    In plain wordsIn mice, GHRP‑2 treatment did not increase lean mass.

    Peptide
    GHRP-2
    Outcome
    No significant changeLean mass
    Study

    mousen: not reported in source

    Npy-/- and wild-type mice
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · subcutaneousAs given in this study (mouse).

    Source sentences

    Summary
    Pre- and posttreatment analysis of body composition indicated increased fat mass and bone mass but not lean mass.
    1 context sentence
    Summary · context
    Because such adiposity was thought to be mediated by hypothalamic NPY neurons, we investigated by which mechanism a synthetic ghrelin receptor agonist, GHRP-2, would generate a positive energy balance in NPY-deficient [Npy(-/-) mice] and wild-type controls.
  7. 07AnimalAnimal study (in vivo)Efficacy outcome

    In GHRP‑2-treated mice, the respiratory quotient was increased, which the authors read as preservation of fat.

    In plain wordsIn mice, GHRP‑2 raised the respiratory quotient, which the authors read as fat being preserved.

    Peptide
    GHRP-2
    Outcome
    IncreaseRespiratory quotient
    Study

    mousen: not reported in source

    Npy-/- and wild-type mice
    Outcome group
    Energy expenditure and thermogenesis · Metabolic and weight
    Studied dose
    Dose not stated · subcutaneousAs given in this study (mouse).

    Source sentences

    Summary
    Respiratory quotient was increased in GHRP-2-treated mice, indicating preservation of fat.
    1 context sentence
    Summary · context
    Because such adiposity was thought to be mediated by hypothalamic NPY neurons, we investigated by which mechanism a synthetic ghrelin receptor agonist, GHRP-2, would generate a positive energy balance in NPY-deficient [Npy(-/-) mice] and wild-type controls.
  8. 08AnimalAnimal study (in vivo)Mechanism

    In mice, hypothalamic mRNA levels of agouti-related protein (AGRP) increased after GHRP‑2 treatment.

    In plain wordsIn mice, GHRP‑2 treatment raised the brain signal for a hunger-promoting protein called AGRP.

    Peptide
    GHRP-2
    Outcome
    IncreaseHypothalamic AGRP mRNA
    Study

    mousen: not reported in source

    Npy-/- and wild-type mice
    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    Dose not stated · subcutaneousAs given in this study (mouse).

    Source sentences

    Summary
    Hypothalamic mRNA levels of agouti- related protein (AGRP), an orexigenic melanocortin receptor antagonist, increased after GHRP-2 treatment.
    1 context sentence
    Summary · context
    Because such adiposity was thought to be mediated by hypothalamic NPY neurons, we investigated by which mechanism a synthetic ghrelin receptor agonist, GHRP-2, would generate a positive energy balance in NPY-deficient [Npy(-/-) mice] and wild-type controls.

Studies that did not test the peptide alone1

In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking GHRP-2.

  1. 09AnimalNot a test of GHRP-2 aloneAnimal study (in vivo)Mechanism

    In Npy-/- mice, competitive blockade of AGRP action by the melanocortin-receptor agonist MT-II prevented GHRP-induced weight gain.

    In plain wordsIn mice lacking NPY, the drug MT-II prevented the weight gain that GHRP treatment caused.

    Peptide
    GHRP-2
    Outcome
    DecreaseGHRP-induced weight gain with MT-II
    Study

    mousen: not reported in source

    Npy-/- and wild-type mice
    Outcome group
    Body weight · Metabolic and weight

    Source sentences

    Summary
    Competitive blockade of AGRP action by melanocortin-receptor agonist MT-II prevented GHRP-induced weight gain in Npy(-/-) mice.
    1 context sentence
    Summary · context
    Because such adiposity was thought to be mediated by hypothalamic NPY neurons, we investigated by which mechanism a synthetic ghrelin receptor agonist, GHRP-2, would generate a positive energy balance in NPY-deficient [Npy(-/-) mice] and wild-type controls.

    In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-2.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Versions 4 to 18Current

    28 Oct 2026, 02:02 UTC

    The same notice was added 15 times, first on 13 Oct 2026, 21:44 UTC. The status did not change between them.

    Study results updated

  2. Version 3

    13 Oct 2026, 16:31 UTC

    Study data updated · source update from Europe PMC

  3. Version 2

    10 Oct 2026, 09:43 UTC

    Study results updated

  4. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.